Morpholine → 2-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-N-(1-(cyclopentyl-methylsulfonyl)azetidin-3-yl)-5-fluoropyrimidin-4-amine

HRID 74882Notizen

Reaktionsgleichung

Reaktionsgleichung von HRID 74882
Cl.[NH:2]1[CH2:5][CH:4]([NH:6][C:7]2[C:12]([F:13])=[CH:11][N:10]=[C:9]([C:14]3[C:22]4[C:17](=[N:18][CH:19]=[C:20]([Cl:23])[CH:21]=4)[N:16](S(C4C=CC(C)=CC=4)(=O)=O)[CH:15]=3)[N:8]=2)[CH2:3]1.CCN(C(C)C)C(C)C.[CH:43]1([CH2:48][S:49](Cl)(=[O:51])=[O:50])[CH2:47][CH2:46][CH2:45][CH2:44]1.N1CCOCC1>ClCCl>[Cl:23][C:20]1[CH:21]=[C:22]2[C:14]([C:9]3[N:8]=[C:7]([NH:6][CH:4]4[CH2:5][N:2]([S:49]([CH2:48][CH:43]5[CH2:47][CH2:46][CH2:45][CH2:44]5)(=[O:51])=[O:50])[CH2:3]4)[C:12]([F:13])=[CH:11][N:10]=3)=[CH:15][NH:16][C:17]2=[N:18][CH:19]=1

Komponenten

6

Edukt 4

HCID 8083MorpholineHCID 81531DiisopropylethylamineHCID 2735404Cyclopentylmethanesulfonyl ChlorideHCID 67284924N-(azetidin-3-yl)-2-(5-chloro-1-tosyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4-amine hydrochloride2×

Produkt 1

HCID 680079372-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-N-(1-(cyclopentyl-methylsulfonyl)azetidin-3-yl)-5-fluoropyrimidin-4-amineAusbeute 88 %

Reagenzien, Katalysatoren, Lösungsmittel 1

HCID 6344DichloromethaneLösungsmittel

Versuchsvorschrift

To a stirred solution of N-(azetidin-3-yl)-2-(5-chloro-1-tosyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-5-fluoropyrimidin-4-amine hydrochloride, 6c, (0.03 g, 0.06 mmol) in dichloromethane (1 mL) was added iPr2NEt (0.33 μL, 1.90 mmol) followed by cyclopentylmethanesulfonyl chloride (0.01 g, 0.06 mmol). The resulting mixture was stirred 30 minutes at room temperature at which time LCMS showed complete reaction. Morpholine (0.20 mL) was added and the solution evaporated to dryness. The resulting residue was dissolved in methanol (2 mL) then treated with 25% sodium methoxide/methanol (0.5 mL) and heated at 60° C. in sealed tube for 10 minutes. The solution was quenched with aqueous saturated NH4Cl solution (0.5 mL) then evaporated to dryness. The resulting residue was dissolved in DMSO and purified by reverse phase HPLC (ammonium formate buffer) to afford 27.4 mg (88% yield) of the desired product, 469, as a solid. LCMS RT=3.1 min, ES+465.

Aufarbeitung

  1. customreaction
  2. customthe solution evaporated to dryness
  3. dissolutionThe resulting residue was dissolved in methanol (2 mL)
  4. additionthen treated with 25% sodium methoxide/methanol (0.5 mL)
  5. temperatureheated at 60° C. in sealed tube for 10 minutes
  6. customThe solution was quenched with aqueous saturated NH4Cl solution (0.5 mL)
  7. customthen evaporated to dryness
  8. dissolutionThe resulting residue was dissolved in DMSO
  9. custompurified by reverse phase HPLC (ammonium formate buffer)

Quellen und Nachweise

ORD-Eintrag
ord-c2b29f0fc7b041fe86c0a451d685ed86
Quelldatensatz
uspto-grants-2014_09
Patentnummer
US08829007B2

Notizen zur Reaktion

Wird geladen…